GW Pharma’s Epidyolex reclassified in UK to lower control level

The UK Home Office has reclassified GW Pharmaceuticals plc’s (NASDAQ:GWPH) Epidyolex (cannabidiol) to Schedule 5 from Schedule 2, a lower level of control that will reduce costs and enable the medicine to be dispensed more easily according to COO Chris Tovey.

The drug is approved in the UK for the adjunctive therapy for seizures associated with Lennox Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for patients at least two years old.

https://seekingalpha.com/news/3585620-gw-pharmas-epidyolex-reclassified-in-uk-to-lower-control-level